An investor's guide to Primary Health Care Limited

Primary Health Care Limited's (ASX:PRY) share price is at a multi-year low – Is now the time to buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A quick look at the 12-month price chart for Primary Health Care Limited (ASX: PRY) will leave most shareholders feeling pretty disappointed. After reaching $5.50 a share in late March of this year, the shares are now trading closer to $3.50 – a 36% decline and now at levels not seen since 2012.

Perhaps more disappointing for shareholders is Primary Health Care's relative performance against other companies in the sector. As the chart below demonstrates, Primary Health Care has significantly underperformed against other healthcare companies such as Ramsay Health Care Limited (ASX: RHC) and Sonic Healthcare Limited (ASX: SHL).

Source: Google Finance

Source: Google Finance

Interestingly, it appears there are a large group of investors and traders who are confident of further falls in the share price. According to ASIC, more than 12.5% of the issued stock is currently held in short positions. That puts Primary Health Care in the same league as Worleyparsons Limited (ASX: WOR) and Cabcharge Australia Limited (ASX: CAB) – two companies facing serious structural and industry headwinds.

Investors must now ask the question – Is Primary Health Care at bargain prices or could there be further falls to come?

To give investors a better understanding of the company, here are some important points that could provide a clearer picture of where it is heading.

Background

Primary Health Care is a diversified healthcare company with a market capitalisation of $1.8 billon.

It has a number of distinct business units including pathology, imaging, medical centres and medical software.

Performance

In FY15, Primary Health Care reported revenues of $1.618 billion, an increase of 6.2%. Excluding the proceeds from an ATO settlement, underlying net profit after tax (NPAT) grew by only 3.9% to $119.1 million.

Margins have been under pressure recently as a result of Medicare reimbursement cuts, subdued patient volumes, increased investment in medical centre operations and the loss of a imaging operation in Buderim. The result of these factors has seen EBIT margins decline from 16.8% t0 15.3%.

Balance Sheet

Primary Health Care carries more than $1.2 billion worth of interest bearing liabilities on its balance sheet and less than $50 million in cash. This gives the company a net debt to equity ratio of nearly 48%.

It is interesting to note that more than 71% of the company's assets as stated on the balance sheet comes from goodwill with a carrying value of more than $2.8 billion.

Strategic Review 

The company has recently completed a strategic review where it was able to identify a number of areas for improvement it believes could increase NPAT by 2-3% annually.

Some of these initiatives include:

  • Expanding large scale medical centres where a number of different healthcare professionals co-exist to meet all of the customers' needs in one place.
  • Improving recruitment and retention of key employees as well as improved training for practitioners
  • Increasing the scale of its imaging operations to gain the benefits of lower costs.
  • Expanding its pathology operations to much larger overseas markets.
  • Establishing a property trust to fund new centres and clinics

A number of these strategies will take a number of years to implement, but if successfully implemented, could position Primary Health Care for a much improved performance in the future.

Shareholder Returns

The long-term returns from Primary Health Care have been disappointing to date. Over the last 10 years, the company has delivered a total shareholder return, each year on average, of negative (-) 4.2%. This is well below the total return delivered from the broader market as well as the healthcare sector.

Valuation

Following the significant fall in the share price, Primary Health Care is now trading on a price-to-earnings ratio of 15.4.

It is also offering a partially franked dividend yield of 5.6% based on the company's most recent full year dividend of 20 cents. Investors should note however, some analysts are forecasting this dividend to fall to 17.7 cents for FY16.

Foolish takeaway

The outlook for the broader healthcare sector remains positive considering the long-term tailwinds the industry is expected to benefit from over the next decade or so.

The short-term outlook for Primary Health Care is less clear, however, as a result of the ongoing Medicare Benefits Schedule review, high debt load and the recent pressure on its margins.

The company relies heavily on funding from the Federal government for many of the services it offers and until the review is completed, the uncertainty seems to be compounding the negative sentiment surrounding the stock.

Investors considering buying into Primary Health Care may hold off until the Medicare review is completed or at the very least until an update is provided at the AGM which will be held on November 26.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »